579 692
Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at
http://dx.doi.org/10.1016/j. eururo.2016.09.032.
References
[1]
MacDonald R, Wilt TJ. Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a sys- tematic review of efficacy and adverse effects. Urology 2005;66: 780–8.[2]
MacDonald R, Wilt TJ, Howe RW. Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruc- tion: a systematic review of efficacy and adverse effects. BJU Int 2004;94:1263–70.
[3]
Wilt TJ, Howe W, MacDonald R. Terazosin for treating symptomatic benign prostatic obstruction: a systematic review of efficacy and adverse effects. BJU Int 2002;89:214–25.[4]
Wilt TJ, MacDonald R, Nelson D. Tamsulosin for treating lower urinary tract symptoms compatible with benign prostatic obstruc- tion: a systematic review of efficacy and adverse effects. J Urol 2002; 167:177–83.[5] Tacklind J, Fink HA, Macdonald R, Rutks I, Wilt TJ. Finasteride for
benign prostatic hyperplasia. Cochrane Database Syst Rev. 2010:
CD006015.
[6]
Hollingsworth JM, Wilt TJ. Lower urinary tract symptoms in men. BMJ 2014;349:g4474.
[7] Viswanathan M, Ansari M, Berkman N, et al. Assessing the risk of
bias of individual studies in systematic reviews of health care
interventions. In: AHRQ, editor. Agency for Healthcare Research
and Quality Methods Guide for Comparative Effectiveness Reviews.
Rockville, MD: AHRQ; 2012. p. 1-A7.
[8]
Fu R, Gartlehner G, Grant M, et al. Conducting quantitative synthe- sis when comparing medical interventions: AHRQ and the Effective Health Care Program. J Clin Epidemiol 2011;64:1187–97.
[9]
IntHout J, Ioannidis JP, Borm GF. The Hartung-Knapp-Sidik- Jonkman method for random effects meta-analysis is straightfor- ward and considerably outperforms the standard DerSimonian- Laird method. BMC Med Res Methodol 2014;14:25.
[10] The Cochrane Collaboration. Review Manager (RevMan) Computer
program. Version 5.2. Copenhagen 2012.
[11] Higgins J, Green S. Cochrane Handbook for Systematic Reviews of
Interventions Version 5.1. 0. The Cochrane Collaboration.
http:// training.cochrane.org/handbook .[12] Berkman ND, Lohr KN, Ansari M, et al. Grading the strength of a
body of evidence when assessing health care interventions for the
effective health care program of the Agency for Healthcare
Research and Quality: an update. AHRQ Publication No. 13(14)-
EHC130-EF. Rockville, MD: Agency for Healthcare Research and
Quality. November 2013.
www.effectivehealthcare.ahrq.gov/reports/final.cfm.
[13]
Pande S, Hazra A, Kundu AK. Evaluation of silodosin in comparison to tamsulosin in benign prostatic hyperplasia: a randomized con- trolled trial. Indian J Pharmacol 2014;46:601–7.[14]
Yokoyama T, Hara R, Fujii T, Jo Y, Miyaji Y, Nagai A. Comparison of two different alpha1-adrenoceptor antagonists, tamsulosin and silodosin, in the treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a pro- spective randomized crossover study. Low Urin Tract Symptoms 2012;4:14–8.[15]
Yu HJ, Lin AT, Yang SS, et al. Noninferiority of silodosin to tamsu- losin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). BJU Int 2011; 108:1843–8.[16]
Yokoyama T, Hara R, Fukumoto K, et al. Effects of three types of alpha-1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. Int J Urol 2011;18:225–30.
[17]
Watanabe T, Ozono S, Kageyama S. A randomized crossover study comparing patient preference for tamsulosin and silodosin in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. J Int Med Res 2011;39:129–42.
[18]
Chapple CR, Montorsi F, Tammela TL, et al. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial per- formed in Europe. Eur Urol 2011;59:342–52.[19]
Miyakita H, Yokoyama E, Onodera Y, et al. Short-term effects of crossover treatment with silodosin and tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia. Int J Urol 2010;17:869–75.[20]
Kawabe K, Yoshida M, Homma Y, Silodosin Clinical Study G. Silo- dosin, a new alpha1A-adrenoceptor-selective antagonist for treat- ing benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 2006;98:1019–24.
[21]
Takeshita H, Moriyama S, Arai Y, et al. Randomized crossover comparison of the short-term efficacy and safety of single half- dose silodosin and tamsulosin hydrochoride in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. Low Urin Tract Symptoms 2016;8:38–43.[22]
Manjunatha R, Pundarikaksha HP, Madhusudhana HR, Amarkumar J, Hanumantharaju BK. A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia. Indian J Pharmacol 2016;48:134–40.[23]
Ceylan C, Ertas K, Dogan S, Gunes ZE. The comparison alpha- blocker+M3 selective anti-muscarinic combined therapy and alpha-blocker monotherapy. J Clin Anal Med 2012;3:33–5.[24]
Singh I, Garg G, Agarwal V. Tamsulosin and darifenacin versus tamsulosin monotherapy for BPH with accompanying overactive bladder. J Clin Diagn Res 2015;9:PC08–11.
[25]
Kaplan SA, Roehrborn CG, Gong J, Sun F, Guan Z. Add-on fesoter- odine for residual storage symptoms suggestive of overactive bladder inmen receiving alpha-blocker treatment for lower urinary tract symptoms. BJU Int 2011;109:1831–40.[26]
Konstantinidis C, Samarinas M, Andreadakis S, Xanthis S, Skriapas K. Lower urinary tract symptoms associated with benign prostatic hyperplasia: combined treatment with fesoterodine fumarate extended-release and tamsulosin—a prospective study. Urol Int 2013;90:156–60.
[27]
MacDiarmid SA, Peters KM, Chen A, et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clin Proc 2008; 83:1002–10.
[28]
Ko K, Yang DY, Lee WK, Kim, et al. Effect of improvement in lower urinary tract symptoms on sexual function in men: tamsulosin monotherapy vs. combination therapy of tamsulosin and solifena- cin. Korean J Urol 2014;55:608–14.
[29]
Kaplan SA, McCammon K, Fincher R, Fakhoury A, He W. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. J Urol 2009;182: 2825–30.
[30]
Lee SH, Byun SS, Lee SJ, Kim KH, Lee JY. Effects of initial combined tamsulosin and solifenacin therapy for overactive bladder and blad- der outlet obstruction secondary to benign prostatic hyperplasia:E U R O P E A N U R O L O G Y 7 1 ( 2 0 1 7 ) 5 7 0 – 5 8 1
579